( NASDAQ-NMS:ICPT )

News from intercept pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 14, 2013, 06:05 ET Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results

 Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...


Oct 08, 2013, 21:02 ET Intercept Announces Pricing of Public Offering of Common Stock By Selling Stockholders

 Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...


Oct 01, 2013, 16:05 ET Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)(Intercept), a clinical stage biopharmaceutical company focused on the development and...


Aug 13, 2013, 06:00 ET Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results

Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...


Aug 05, 2013, 06:00 ET Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...


Jul 01, 2013, 07:05 ET Intercept Pharmaceuticals to Present at the JMP Securities Healthcare Conference

 Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...


Jun 24, 2013, 13:30 ET Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares

 Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...


Jun 18, 2013, 20:25 ET Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock

 Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...


Jun 17, 2013, 06:00 ET Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock

 Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...


May 23, 2013, 08:03 ET Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference

 Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...


May 20, 2013, 08:00 ET Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea

  Intercept Pharmaceuticals, Inc. ("Intercept", NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...


Sep 04, 2012, 16:01 ET Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

 Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel...


Aug 09, 2012, 17:24 ET Intercept Pharmaceuticals Closes $30 Million Series C Financing

 Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel...


Aug 09, 2011, 07:05 ET Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes

Intercept Pharmaceuticals, Inc. (Intercept) and Les Laboratoires Servier (Servier) today announced that they have entered into a worldwide ex-U.S....


Mar 31, 2011, 13:00 ET Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis

Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind  Phase II clinical trial...


Mar 30, 2011, 06:03 ET Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease

Dainippon Sumitomo Pharma Co, Ltd. (DSP) and Intercept Pharmaceuticals, Inc. (Intercept) today announced that they have entered into an exclusive...


Mar 29, 2011, 07:00 ET Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASH

Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National...


Jul 28, 2010, 08:00 ET Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic...


Apr 13, 2010, 08:00 ET Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL

Intercept Pharmaceuticals, Inc., today announced the presentation of the results from its recently completed Phase II clinical trial of INT-747...


Jan 25, 2010, 08:00 ET Intercept Pharmaceuticals Raises $25 Million Series B Financing

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic...


Oct 27, 2009, 08:00 ET Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis

Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of...


Oct 01, 2009, 22:00 ET Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease

Intercept Pharmaceuticals, Inc., has announced that its first-in-class farnesoid X receptor (FXR) agonist INT-747 has met the primary...


Sep 01, 2009, 17:14 ET Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity

Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism. Bile acid activation of the G protein-coupled...


Aug 07, 2008, 01:00 ET Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling

NEW YORK, Aug. 7 /PRNewswire/ -- Historically, bile acids have been recognized primarily as natural detergents that regulate the absorption of...


Jan 03, 2008, 00:00 ET Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer

NEW YORK, Jan. 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapeutics for the...